GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » EV-to-EBITDA

InnoCare Pharma (HKSE:09969) EV-to-EBITDA : -4.02 (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InnoCare Pharma's enterprise value is HK$1,487.3 Mil. InnoCare Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-369.7 Mil. Therefore, InnoCare Pharma's EV-to-EBITDA for today is -4.02.

The historical rank and industry rank for InnoCare Pharma's EV-to-EBITDA or its related term are showing as below:

HKSE:09969' s EV-to-EBITDA Range Over the Past 10 Years
Min: -216.63   Med: -29.74   Max: 1.57
Current: -4.81

During the past 7 years, the highest EV-to-EBITDA of InnoCare Pharma was 1.57. The lowest was -216.63. And the median was -29.74.

HKSE:09969's EV-to-EBITDA is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 10.33 vs HKSE:09969: -4.81

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), InnoCare Pharma's stock price is HK$4.57. InnoCare Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.490. Therefore, InnoCare Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


InnoCare Pharma EV-to-EBITDA Historical Data

The historical data trend for InnoCare Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma EV-to-EBITDA Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -31.89 851.12 -17.12 -8.25

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.12 -9.12 -3.56 -8.25 -

Competitive Comparison of InnoCare Pharma's EV-to-EBITDA

For the Biotechnology subindustry, InnoCare Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's EV-to-EBITDA falls into.



InnoCare Pharma EV-to-EBITDA Calculation

InnoCare Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1487.282/-369.738
=-4.02

InnoCare Pharma's current Enterprise Value is HK$1,487.3 Mil.
InnoCare Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-369.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCare Pharma  (HKSE:09969) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InnoCare Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.57/-0.490
=At Loss

InnoCare Pharma's share price for today is HK$4.57.
InnoCare Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-0.490.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


InnoCare Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Cui Jisong
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner

InnoCare Pharma (HKSE:09969) Headlines

No Headlines